- FDA approves generic versions of Plavix
- FDA gives new approval to Bristol-Myers Squibb's, Lilly's Erbitux
- FDA OKs Abilify as maintenance treatment for bipolar disorder
- As innovaters prep for patent cliff, generics prosper from patent losses
- Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment
NEW YORK Bristol-Myers Squibb formally has begun its tender offer for biotech company ZymoGenetics, the drug maker said Friday.
Bristol-Myers Squibb announced its intent to acquire the Seattle-based company earlier this week for $885 million, or $9.75 per share.
The buyout, approved by the boards of both companies, gives Bristol-Myers Squibb ownership of Recothrom, a drug used to control bleeding during surgical procedures, and pegylated-interferon lambda, a treatment for hepatitis C that is in mid-stage clinical trials that the two companies had been developing. ZymoGenetics also had been developing IL-21, a treatment in mid-stage trials for melanoma .